Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network

<b>Background:</b> The ASPIRE (NCT01080391) phase 3 trial showed the efficacy of carfilzomib, lenalidomide and dexamethasone (KRd) triplet for relapse and refractory multiple myeloma (RRMM). However, little is known about safety and efficacy of KRd outside a clinical trial context. <b...

詳細記述

保存先:
書誌詳細
主要な著者: Concetta Conticello, Alessandra Romano, Vittorio Del Fabro, Enrica Antonia Martino, Valeria Calafiore, Giuseppe Sapienza, Valerio Leotta, Marina Silvia Parisi, Uros Markovic, Bruno Garibaldi, Salvatore Leotta, Emilia Cotzia, Vanessa Innao, Donato Mannina, Santo Neri, Maurizio Musso, Renato Scalone, Clotilde Cangialosi, Francesco Acquaviva, Giovanni Cardinale, Anxur Merenda, Cinzia Maugeri, Giuseppina Uccello, Massimo Poidomani, Giuseppe Longo, Melania Carlisi, Daniele Tibullo, Francesco Di Raimondo
フォーマット: Artigo
言語:Inglês
出版事項: MDPI AG 2019-06-01
シリーズ:Journal of Clinical Medicine
主題:
KRd regimen
multiple myeloma
salvage therapy
オンライン･アクセス:https://www.mdpi.com/2077-0383/8/6/877
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料